TABLE 4

Risk Score Performance of Existing Algorithms for Predicting IVIg Nonresponse at Incident KD Presentation

Risk Score (First Author)No. With Missing DataC-IndexSensitivity, %Specificity, %Low Risk Probability of NonresponseHigh Risk Probability of Nonresponse
Egami et al9,a6858.333.378.816.627.1
Lin et al31,b8652.060.645.017.220.7
Kobayashi et al6,c7961.325.486.817.932.7
Sano et al12,d8355.59.294.018.226.1
Qian et al32,e8653.162.143.917.020.8
Sleeper et al7,f8661.6
  • —, not applicable.

  • a High-risk indications: age <6 mo, <4 d with a fever, C-reactive protein level >8 mg/dL, platelet count <300 × 109 per L, and alanine aminotransferase level >80 IU/L.

  • b High-risk indications: lymphadenopathy, neutrophil percentage ≥60%, and albumin level ≤3.5 g/dL.

  • c High-risk indications: age <12 mo, <4 d with a fever, C-reactive protein level≥10 mg/dL AST level ≥100 IU/L, platelet count ≤300 × 109 per L, and sodium level <133 mEq/L.

  • d High-risk indications: C-reactive protein level≥7 mg/dL, total bilirubin level ≥0.9 mg/dL, and AST level ≥200 IU/L.

  • e High-risk indications: age <6 mo, presence of rash, presence of edema, neutrophil percentage ≥80%, and albumin level <3.5 g/dL.

  • f The Sleeper et al7 score included albumin level, sex, and neutrophil percentage; this score did not have threshold for classifying high and low risk, so sensitivity, specificity, and probabilities of nonresponse could not be calculated.